Diabetes and Vascular Disease
Top Cited Papers
Open Access
- 23 September 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (12), 1527-1532
- https://doi.org/10.1161/01.cir.0000091257.27563.32
Abstract
Diabetes mellitus affects approximately 100 million persons worldwide.1 Five to ten percent have type 1 (formerly known as insulin-dependent) and 90% to 95% have type 2 (non–insulin-dependent) diabetes mellitus. It is likely that the incidence of type 2 diabetes will rise as a consequence of lifestyle patterns contributing to obesity.2 Cardiovascular physicians are encountering many of these patients because vascular diseases are the principal causes of death and disability in people with diabetes. The macrovascular manifestations include atherosclerosis and medial calcification. The microvascular consequences, retinopathy and nephropathy, are major causes of blindness and end-stage renal failure. Physicians must be cognizant of the salient features of diabetic vascular disease in order to treat these patients most effectively. The present review will focus on the relationship of diabetes mellitus and atherosclerotic vascular disease, highlighting pathophysiology and molecular mechanisms (Part I) and clinical manifestations and management strategies (Part II). Abnormalities in endothelial and vascular smooth muscle cell function, as well as a propensity to thrombosis, contribute to atherosclerosis and its complications. Endothelial cells, because of their strategic anatomic position between the circulating blood and the vessel wall, regulate vascular function and structure. In normal endothelial cells, biologically active substances are synthesized and released to maintain vascular homeostasis, ensuring adequate blood flow and nutrient delivery while preventing thrombosis and leukocyte diapedesis.3 Among the important molecules synthesized by the endothelial cell is nitric oxide (NO), which is constitutively produced by endothelial NO synthase (eNOS) through a 5-electron oxidation of the guanidine-nitrogen terminal of l-arginine.4 The bioavailability of NO represents a key marker in vascular health. NO causes vasodilation by activating guanylyl cyclase on subjacent vascular smooth muscle cells.4 In addition, NO protects the blood vessel from endogenous injury—ie, atherosclerosis—by mediating molecular signals that prevent platelet and leukocyte interaction with …Keywords
This publication has 99 references indexed in Scilit:
- High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial CellsCirculation, 2003
- Endothelial dysfunction in diabetesBritish Journal of Pharmacology, 2000
- High-glucose-induced nuclear factor κB activation in vascular smooth muscle cellsCardiovascular Research, 2000
- Not Acute but Chronic Hypertriglyceridemia Is Associated With Impaired Endothelium-Dependent VasodilationArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Oxidation of Tetrahydrobiopterin by Peroxynitrite: Implications for Vascular Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- The Role of Hyperglycaemia and Hyperinsulinaemia in Causing Vascular Dysfunction in DiabetesAnnals of Medicine, 1996
- Activation of Tissue Factor–Induced Coagulation and Endothelial Cell Dysfunction in Non–Insulin-Dependent Diabetic Patients With MicroalbuminuriaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivityThe American Journal of Cardiology, 1991
- Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta.Journal of Clinical Investigation, 1990
- The role of nitric oxide and cGMP in platelet adhesion to vascular endotheliumBiochemical and Biophysical Research Communications, 1987